22 completed, 2 recruiting, 1 terminated, 1 unknown. 27 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 27 | Completed 22, Recruiting 2, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Unknown 1, Withdrawn 1 |
Follow Sitagliptin: new trials by email Literature Review of Sitagliptin trials Research Report on Sitagliptin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sitagliptin in Recurrent/Progressive Grade 4 Glioma Sitagliptin, Bevacizumab - Glioma, Glioblastoma | Phase 1 | Recruiting | Kailin Yang, MD, PhD | 45 | 2026-06-11 | 2026-06-17 |
| Sitagliptin With Pembro in RCC and Melanoma Sitagliptin, Pembrolizumab - Advanced Renal Cell Carcinoma, Advanced Melanoma | Phase 1 | Recruiting | Fernando Maciel Barbosa | 64 | 2026-05-14 | 2026-07-30 |
| A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults. ABBV-722, Midazolam, Metformin - Healthy Volunteers | Phase 1 | Completed | AbbVie | 12 | 2026-04-30 | 2026-08-20 |
| High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD Sitagliptin, Bortezomib, Cyclophosphamide - Bone Marrow Transplant Complications, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Indiana University | 2023-11-01 | 2024-04-29 | |
| Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components Dapagliflozin/sitagliptin FDC, Sitagliptin, Dapagliflozin - Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus) | Phase 1 | Completed | AstraZeneca | 46 | 2022-03-21 | 2022-07-05 |
| Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients placebo, metformin, Sitagliptin - Polycystic Ovary Syndrome, Infertility | Phase 1 / Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 80 | 2020-01-10 | 2021-03-22 |
| Drug Interaction Study Between Dorzagliatin and Sitagliptin Sitagliptin, Dorzagliatin - Patients | Phase 1 | Completed | Hua Medicine Limited | 15 | 2019-01-31 | 2023-02-28 |
| A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM DA-1241, Placebo, Sitagliptin - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Dong-A ST Co., Ltd. | 108 | 2018-08-29 | 2021-02-11 |
| A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes LY3325656, Placebo, Liraglutide - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Eli Lilly and Company | 80 | 2017-05-31 | 2018-08-23 |
| Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Bexagliflozin, Metformin, Glimepiride - Type2 Diabetes Mellitus | Phase 1 | Completed | Theracos | 54 | 2016-11-01 | 2021-07-22 |
| A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection Sitagliptin - Hepato Carcinoma | Phase 1 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 14 | 2016-02-01 | 2026-10-05 |
| The Role of Phosphodiesterase Inhibitors in Incretin Secretion Placebo, Roflumilast/Sitagliptin, Sitagliptin - Healthy Volunteers | Phase 1 | Completed | National Institute on Aging (NIA) | 29 | 2015-02-13 | 2026-10-08 |
| A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients Sitagliptin - Hepatitis C | Phase 1 | Terminated | Institut National de la Santé Et de la Recherche Médicale, France | 3 | 2013-03-01 | 2026-10-07 |
| Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis Sitagliptin - Cystic Fibrosis | Phase 1 | Completed | Nemours Children's Clinic | 6 | 2012-11-01 | 2016-06-14 |
| Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Placebo, Sitagliptin, LEZ763 - Type II Diabetes | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 220 | 2012-03-01 | 2020-12-17 |
| Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion Mixed meal test, Vildagliptin, Sitagliptin - Type 2 Diabetes | Phase 1 | Completed | Michael A. Nauck | 24 | 2011-11-01 | 2016-04-22 |
| A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes LY2189265, Sitagliptin - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Eli Lilly and Company | 29 | 2011-08-01 | 2014-10-07 |
| Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin Sitagliptin, Mitiglinide, Sitagliptin, Mitiglinide - Type 2 Diabetes Mellitus | Phase 1 | Completed | Samsung Medical Center | 26 | 2010-05-01 | 2011-09-07 |
| Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus AZD1656, Sitagliptin - Type 2 Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 12 | 2010-03-01 | 2010-07-01 |
| A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects ASP1941, sitagliptin - Healthy, Pharmacokinetics of ASP1941 | Phase 1 | Completed | Astellas Pharma Inc | 64 | 2010-02-01 | 2010-04-16 |
Showing 20 of 27. Sign in to see all of them.
Diabetes Mellitus, Type 2 (10) · Diabetes Mellitus (3) · Cystic Fibrosis (1) · Diabetes Mellitus, Type 1 (1) · Gastroparesis (1) · Glioblastoma (1) · Glioma (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Infertility (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Polycystic Ovary Syndrome (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
AstraZeneca (3) · Eli Lilly and Company (2) · Institut National de la Santé Et de la Recherche Médicale, France (2) · AbbVie (1) · Astellas Pharma Inc (1) · Boehringer Ingelheim (1) · Dong-A ST Co., Ltd. (1) · European Foundation for the Study of Diabetes (1) · Fernando Maciel Barbosa (1) · GlaxoSmithKline (1) · Hua Medicine Limited (1) · Indiana University (1) · Kailin Yang, MD, PhD (1) · Merck Sharp & Dohme LLC (1) · Michael A. Nauck (1)
United States (14) · Germany (4) · France (3) · South Korea (2) · Australia (1) · China (1) · Iran (1) · Singapore (1) · United Kingdom (1)
Chee W Chia, M.D. (1) · Christoph Kapitza (1) · Fernando Maciel Barbosa, MD (1) · Gregory Tracey, MD (1) · Kailin Yang, MD, PhD (1) · Karen L Jones, PhD (1) · Kyung-Sang Yu, MD, PhD (1) · Larry A Fox, MD (1) · Mason Freeman, M.D. (1)
PMID 22738299, PMID 24249434, PMID 24432999, PMID 25767259, PMID 27137491, PMID 29138226, PMID 30895467, PMID 32720198, PMID 33475138, PMID 39179458
2015 (1)